Featured Press Releases

OncoIncytes Launched by 1Cell.Ai (Previously OneCell Diagnostics) to Integrate Multi-Modal Data for Precision Oncology

OncoIncytes Launched by 1Cell.Ai (Previously OneCell Diagnostics) to Integrate Multi-Modal Data for Precision Oncology

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

PANTHERx® Rare is selected by Calliditas Therapeutics as the specialty pharmacy for TARPEYO®.

  • 03 Sep 2024

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United...

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Bruker Introduces nVista 2P Miniature Microscope

Bruker Introduces nVista 2P Miniature Microscope

Next Generation Gene Therapeutics (NGGT) announces the publication of early clinical trial results for NGGT001, a treatment for Bietti

Next Generation Gene Therapeutics (NGGT) announces the publication of early clinical trial results for NGGT001, a treatment for Bietti's Crystalline Dystrophy (BCD)

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Dr. Alastair Leighton, a biopharma veteran, has been hired as Chief Operating Officer by Chemify

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

Aspera Biomedicines launched its second ADAR1p150 crystallization to the ISS aboard SpaceX CRS-34

  • Aspera Biomedicines Inc.
  • 18 May 2026
Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

Galvanize Therapeutics receives FDA clearance for the Aliya EX Generator, expanding its Aliya Pulsed Electric Field portfolio

  • Galvanize Therapeutics, Inc.
  • 18 May 2026
Peter Menziuso named EVP and President of BD Interventional

Peter Menziuso named EVP and President of BD Interventional

  • BD
  • 18 May 2026
A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

A new real-world case series examines re-induction with ADSTILADRIN in clinical practice

  • Ferring Pharmaceuticals
  • 17 May 2026
Biohack skin longevity with Futurecode Booster

Biohack skin longevity with Futurecode Booster

  • Dermalogica
  • 16 May 2026
ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

ENHERTU received U.S. approval for two new indications in HER2-positive early breast cancer.

  • AstraZeneca
  • 15 May 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.